Clinical trials: Kidney Disease
Hypertension
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
To verify the safety and effectiveness of the renal artery radiofrequency ablation system under the guidance of the three-dimensional cardiac electrophysiological mapping system in the renal denervation of essential hypertension.
- Trial name
- NCT05590871
- Testing
- FlashPoint renal denervation system
- Where
- 27 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Hongdian Medical CO., LTD
Primary IgA Nephropathy
A Trial of HR19042 Capsule in Healthy Chinese Subjects
The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects.
- Trial name
- NCT04887532
- Testing
- HR19042 capsule
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IgAN
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients.
- Trial name
- NCT07606352
- Testing
- STL303
- Where
- 8 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Sitala Bio LTD
Anaemia in Chronic Kidney Disease
A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency
The purpose of the study is to monitor initiated Diafer® therapy administered according to hospital practice and the product labeling in routine clinical practice in haemodialysis patients with Chronic Kidney Disease.
- Trial name
- DINO (NCT02301026)
- Testing
- 5% Iron Isomaltoside 1000
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 209 people
- Sponsor
- Pharmacosmos A/S
Kidney Disease
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy.
- Trial name
- BREAKOUT (NCT05709444)
- Testing
- Bremelanotide, RAAS inhibition therapy
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Palatin Technologies, Inc
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Renal Cancer, GIST
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sunitinib malate will be determined.
- Trial name
- NCT00399152
- Testing
- Perifosine, Sunitinib Malate
- Volunteers
- 15 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
The purpose of this study is to evaluate the effectiveness and safety of bortezomib in participants previously treated for multiple myeloma (cancer of plasma cells in bone marrow causing numerous tumors and characterized by the…
- Trial name
- NCT00718640
- Testing
- Dexamethasone, Bortezomib
- Where
- 5 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Janssen-Ortho Inc., Canada
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Secondary Hyperparathyroidism
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in patients receiving…
- Trial name
- NCT01576146
- Testing
- Etelcalcetide
- Volunteers
- 30 people
- Sponsor
- KAI Pharmaceuticals
Renal Impairment
Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function
To evaluate the effect of renal impairment on the pharmacokinetics (PK) of teduglutide following subcutaneous (SC) administration of 10 mg teduglutide.
- Trial name
- NCT01028768
- Testing
- Teduglutide
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Nycomed
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Pruritus, Cholestasis
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.
- Conditions
- Pruritus, Cholestasis, Kidney Failure
- Trial name
- NCT04510090
- Testing
- EP547
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Escient Pharmaceuticals, Inc
Anemia
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.
This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin.
- Trial name
- NCT00077623
- Testing
- epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera)
- Where
- 90 sites in United States, Belgium and 19 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Renal Cell
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma.
- Trial name
- NCT00726323
- Testing
- foretinib (formerly GSK1363089 or XL880)
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline
Papillary Renal Cell Carcinoma
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally…
- Trial name
- PRCC (NCT07024680)
- Testing
- Observational, None intervention
- Where
- China
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Chronic Renal Failure
Safety Study of TRK-820 for Patient With Hemodialysis
The purpose of this study is to observe pharmacokinetics and safety of nalfurafine hydrochloride in patients receiving hemodialysis.
- Trial name
- TRK-820 (NCT01248650)
- Testing
- nalfurafine hydrochloride
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- SK Chemicals Co., Ltd.
End-Stage Renal Disease
Cook Enforcer Post-Market Study
The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional…
- Trial name
- NCT03552289
- Testing
- Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- Cook Research Incorporated
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.